Top

Published in:

01-06-2019 | Research Article

[⁶⁸Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer

Authors: Nader Hirmas, Akram Al-Ibraheem, Ken Herrmann, Abedalatif Alsharif, Haider Muhsin, Jamal Khader, Ali Al-Daghmin, Samer Salah

Published in: Molecular Imaging and Biology | Issue 3/2019

Abstract

Purpose

In this retrospective study, we compared the diagnostic value of ⁶⁸Gallium prostate-specific membrane antigen positron emission tomography computed tomography ([⁶⁸Ga]PSMA PET/CT) in primary staging of patients with high-risk prostate cancer (PCa), in comparison to CT, magnetic resonance imaging (MRI), and bone scans, and we explored its overall impact on patients’ management plan.

Procedures

Patients with pathological confirmation of PCa with high-risk disease were included in this study. Information on patient demographics, clinical and histopathological findings with Gleason score and initial prostate specific antigen PSA levels, and radiological findings for CT, MRI, bone scan, and [⁶⁸Ga]PSMA PET/CT were retrieved. We stratified the concordance and discordance of each imaging modality on per-patient and per-lesion-site bases.

Results

Twenty-one patients with high-risk disease were included in this study. [⁶⁸Ga]PSMA PET/CT revealed a significantly higher concordance rate (90 %) compared to the concordance rates of bone scan (75 %), MRI (73 %), and CT (60 %). [⁶⁸Ga]PSMA PET/CT had a similar accuracy to MRI in detecting prostate lesions but a higher accuracy for suspicious pelvic lymph nodes (95.2 % vs. 80 %). It also superseded CT scan in detecting suspicious pelvic lymph nodes (95.2 % vs. 75 %) and extra-pelvic lymph nodes (100 % vs. 75 %), as well as bone lesions via bone scan (100 % vs. 62.5 %). [⁶⁸Ga]PSMA PET/CT changed the management in 11 patients (52 %).

Conclusions

[⁶⁸Ga]PSMA PET/CT is an invaluable imaging modality in the assessment of primary high-risk PCa with great potential for the detection of lymph node spread and bone metastases that would impact the management plan.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRef

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013. Eur Urol 65:124–137CrossRefPubMed

Fitzmaurice C, Dicker D, Pain A et al (2015) The global burden of cancer 2013. JAMA Oncol 1:505–527CrossRefPubMed

European Association of Urology. Guidelines on prostate cancer. http://uroweb.org/guideline/prostatecancer/

Maurer T, Eiber M, Schwaiger M, Gschwend JE (2016) Current use of PSMA-PET in prostate cancer management. Nat Rev Urol 13:226–235CrossRefPubMed

Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U (2015) The diagnostic value of PET/CT imaging with the ⁶⁸Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197–209CrossRefPubMed

Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, Graner FP, Kubler H, Haberhorn U, Eisenhut M, Wester HJ, Gschwend JE, Schwaiger M (2015) Evaluation of hybrid ⁶⁸Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56:668–674CrossRefPubMed

Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, Bektic J, Horninger W, Lukas P, Decristoforo C, Castellucci P, Fanti S, Virgolini IJ (2015) ⁶⁸Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 42:1284–1294CrossRefPubMed

Eder M, Schäfer M, Bauder-Wüst U, Hull WE, Wängler C, Mier W, Haberkorn U, Eisenhut M (2012) ⁶⁸Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23:688–697CrossRefPubMed

10.

von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G (2016) ⁶⁸Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus. https://doi.org/10.1016/j.euf.2016.11.002

11.

Corfield J, Perera M, Bolton D, Lawrentschuk N (2018) ⁶⁸Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol 36:519–527CrossRefPubMed

12.

D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974CrossRefPubMed

13.

Fanti S, Minozzi S, Morigi JJ, Giesel F, Ceci F, Uprimny C, Hofman MS, Eiber M, Schwarzenbock S, Castellucci P, Bellisario C, Chauvie S, Bergesio F, Emmett L, Haberkorn U, Virgolini I, Schwaiger M, Hicks RJ, Krause BJ, Chiti A (2017) Development of standardized image interpretation for ⁶⁸Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. Eur J Nucl Med Mol Imaging 44:1622–1635CrossRefPubMed

14.

Wright GL Jr, Grob BM, Haley C et al (1996) Upregulation of prostate-specific membrane antigen after androgen deprivation therapy. Urol 48:326–334CrossRefPubMed

15.

Silver DA, Pelicer I, Fair WR et al (1997) Prostate specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85PubMed

16.

Dewes S, Schiller K, Sauter K, Eiber M, Maurer T, Schwaiger M, Gschwend JE, Combs SE, Habl G (2016) Integration of ⁶⁸Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. Radiat Oncol 11:73. https://doi.org/10.1186/s13014-016-0646-2 CrossRefPubMedPubMedCentral

17.

Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habl G, Kopka K, Afshar-Oromieh A, Debus J, Haberkorn U, Giesel FL (2016) ⁶⁸Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging 43:34–41CrossRefPubMed

18.

Virgolini I, Decristoforo C, Haug A et al (2017) Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging 45:471–495CrossRefPubMedPubMedCentral

19.

Budäus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, Graefen M, Steuber T, Rosenbaum C (2016) Initial experience of ⁶⁸Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 69:393–396CrossRefPubMed

20.

van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, Stricker PD (2017) Prospective evaluation of ⁶⁸gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int 119:209–215CrossRefPubMed

21.

Jochumsen MR, Dias AH, Bouchelouche K (2018) Benign traumatic rib fracture: a potential pitfall on ⁶⁸Ga-prostate-specific membrane antigen PET/CT for prostate cancer. Clin Nucl Med 43:38–40CrossRefPubMed

22.

De Coster L, Sciot R, Everaerts W et al (2017) Fibrous dysplasia mimicking bone metastasis on ⁶⁸GA-PSMA PET/MRI. Eur J Nucl Med Mol Imaging 44:1607–1608CrossRefPubMed

23.

Artigas C, Alexiou J, Garcia C, Wimana Z, Otte FX, Gil T, van Velthoven R, Flamen P (2016) Paget bone disease demonstrated on ⁶⁸Ga-PSMA ligand PET/ CT. Eur J Nucl Med Mol Imaging 43:195–196CrossRefPubMed

24.

Bourgeois S, Gykiere P, Goethals L, Everaert H, de Geeter FW (2016) Aspecific uptake of ⁶⁸GA-PSMA in Paget disease of the bone. Clin Nucl Med 41:877–878CrossRefPubMed

25.

Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schäfer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C (2017) F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 44:678–688CrossRefPubMed

Title: [68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer
Authors: Nader Hirmas
Akram Al-Ibraheem
Ken Herrmann
Abedalatif Alsharif
Haider Muhsin
Jamal Khader
Ali Al-Daghmin
Samer Salah
Publication date: 01-06-2019
Publisher: Springer International Publishing
Published in: Molecular Imaging and Biology / Issue 3/2019
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-018-1278-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

[⁶⁸Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer

Abstract

Purpose

Procedures

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Procedures

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

Ferumoxytol Can Be Used for Quantitative Magnetic Particle Imaging of Transplanted Stem Cells

Sparse Detector Configuration in SiPM Digital Photon Counting PET: a Feasibility Study

The Complexity and Fractal Geometry of Nuclear Medicine Images

SPECT/CT Imaging of Mycobacterium tuberculosis Infection with [125I]anti-C3d mAb

Physiological Whole-Brain Distribution of [18F]FDOPA Uptake Index in Relation to Age and Gender: Results from a Voxel-Based Semi-quantitative Analysis

Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers